ライフサイエンスコーパス: keratoconus

1 ens wear, post-laser refractive surgery, and keratoconus).

2 0 early-stage keratoconus and 83 established keratoconus.

3 eratoconus compared with those with moderate keratoconus.

4 tric first-degree relatives of patients with keratoconus.

5 ween the left and right eyes at the onset of keratoconus.

6 significantly greater risk of progression of keratoconus.

7 within the stroma of patients with advanced keratoconus.

8 e set out to describe the natural history of keratoconus.

9 onsible for corneal abnormalities similar to keratoconus.

10 rmal eyes of patients with highly asymmetric keratoconus.

11 slinked in corneal tissue as a treatment for keratoconus.

12 Fifty eyes of 50 participants with keratoconus.

13 the conventional protocol to treat pediatric keratoconus.

14 ccess of the toric IOL implantation, even in keratoconus.

15 ease, which is typically called forme fruste keratoconus.

16 s safe and moderately effective for advanced keratoconus.

17 e rates of scleral lens correction in severe keratoconus.

18 e was the annual incidence and prevalence of keratoconus.

19 s obtained using 3 tomographers in eyes with keratoconus.

20 the corneal stroma of patients with advanced keratoconus.

21 K (9 mm) as the optimal surgical approach to keratoconus.

22 e for the cost-effectiveness of early CXL in keratoconus.

23 onal management with PKP in the treatment of keratoconus.

24 atible with the diagnosis of early stages of keratoconus.

25 nking (CXL) for the treatment of progressive keratoconus.

26 y at a tertiary eye care center for advanced keratoconus.

27 d healing after epi-off CXL in patients with keratoconus.

28 oor visual outcomes after big-bubble DALK in keratoconus.

29 s-linking (CXL) in patients with progressive keratoconus.

30 eal wound healing after CXL in patients with keratoconus.

31 fter PK, occurred among the 56 patients with keratoconus.

32 ct long-term corneal status in patients with keratoconus.

33 orneal cross-linking is widely used to treat keratoconus.

34 achieved in eyes with progressive, advanced keratoconus.

35 AS-OCT confirmed the diagnosis of posterior keratoconus.

36 corneal densitometry after CXL and CRXL for keratoconus.

37 s not been previously described in posterior keratoconus.

38 sepithelial CXL for treatment of progressive keratoconus.

39 for some patients to halt the progression of keratoconus.

40 orneal collagen cross-linking in progressive keratoconus.

41 m; P < 0.001) between those with and without keratoconus.

42 relevance when assessing for progression of keratoconus.

43 necessary to initiate an early treatment of keratoconus.

44 All patients undergoing CXL had progressive keratoconus.

45 ers (20 eyes) and 69 patients (69 eyes) with keratoconus.

46 activators as future treatment strategies in keratoconus.

47 ) for the association between BMI groups and keratoconus.

48 xtrusion happened often in advanced cases of keratoconus.

49 the independent association between BMI and keratoconus.

50 (at 2 years) to halt disease progression in keratoconus.

51 e how obesity is involved in the progress of keratoconus.

52 ignificantly worse repeatability in moderate keratoconus.

53 procedure for the treatment of all stages of keratoconus.

54 tely effective for the treatment of advanced keratoconus.

55 lue, CDVA, and UCVA in eyes with progressive keratoconus 1 year after treatment, with an excellent sa

56 tical basis for two clinical observations on keratoconus: (1) optical performance of keratoconic eyes

57 In mild keratoconus, 11 of 18 (61.1%) anterior corneal, 7 of 14

58 tandard CL) for the treatment of progressive keratoconus 12 months after the operation.

59 ient analysis revealed 32 patients as having keratoconus (17.5%), while 35 patients (19.1%) were labe

60 edema mostly affecting elderly individuals; keratoconus (27%), a corneal disease that slowly deforms

61 patients; using Krumeich's classification of keratoconus, 3 eyes were found to be at stage 1, 3 at st

62 3.7+/-5.9 years) than patients with no acute keratoconus (32.7+/-11.3 years).

63 The main indication for DALK was keratoconus (67.2%, n = 397), and pneumatic dissection w

64 s to the development of eye diseases such as keratoconus, a disease in which the cornea thins and bul

65 Keratoconus, a progressive corneal ectasia, is a complex

66 eye randomly selected from 118 patients with keratoconus; a nonoperated ectatic eye from 57 patients

67 DALK for keratoconus achieves early results similar to those publ

68 2 D), Hoffer Q (1.30 D), and Holladay 2 with keratoconus adjustment (1.32 D).

69 This study enrolled 227 keratoconus-affected eyes that underwent DALK.

70 Keratoconus affects 86 in 100 000 people, causing visual

71 utcome measure was clinical stabilization of keratoconus after 1 year, defined as a maximal keratomet

72 primary outcome measure was stabilization of keratoconus after 12 months through analysis of maximum

73 There were 11.5%-15.5% of patients with keratoconus aged less than 11 years, 18.0% aged 12-15 ye

74 In stage 3 keratoconus, all nonmodified formulas had a hyperopic me

75 There was a greater prevalence of keratoconus among obese adolescents (270/100,000) than o

76 cally unaffected eyes with highly asymmetric keratoconus and 178 eyes from 178 patients with bilatera

77 ributed in 82 normal corneas, 40 early-stage keratoconus and 83 established keratoconus.

78 re 18 to 28 years of age and had progressive keratoconus and a plan to be treated with CXL at Umea Un

79 l with epithelial off CXL, if diagnosed with keratoconus and a progression in Kmax of more than one d

80 ion resulted in comparable representation of keratoconus and ectasia after refractive surgery in the

81 Genome-wide association studies for keratoconus and for quantitative traits such as central

82 BMI should be considered a risk factor for keratoconus and further research should elucidate how ob

83 are linked to several pathologies, including keratoconus and glaucoma.

84 ickness measurements may be achieved in both keratoconus and healthy eyes with the MS-39.

85 ting highly repeatable measurements for both keratoconus and healthy eyes.

86 f additional value in discriminating between keratoconus and healthy eyes.

87 ty and sensitivity in discriminating between keratoconus and healthy eyes.

88 iated with several ocular diseases including keratoconus and macular degeneration.

89 cs in patients with keratoconus, subclinical keratoconus and normal corneas.

90 med by the same operator with Pentacam HR in keratoconus and normal eyes.

91 e for visual rehabilitation in children with keratoconus and poor CDVA.

92 d pediatric patients (aged </=14 years) with keratoconus and poor corrected distance visual acuity (C

93 in microscopy may add value for diagnosis of keratoconus and potentially for screening subjects at ri

94 factor for various ocular diseases, such as keratoconus and primary open angle glaucoma.

95 he relevant age category for newly diagnosed keratoconus and the annual incidence of newly diagnosed

96 be a case of a rare association of bilateral keratoconus and unilateral essential iris atrophy and to

97 We report a rare association of bilateral keratoconus and unilateral essential iris atrophy in a 3

98 neal centre in the opposite direction of the keratoconus apex (direction (ax) CB).

99 through the central point of the cornea and keratoconus apex; second, as the perpendicular axis) to

100 for target refractive aims in each stage of keratoconus are given.

101 nd understanding the roles of these genes in keratoconus are warranted.

102 rameters were strong enough to differentiate keratoconus (AUC > 0.9).

103 to propose a diagnostic model of subclinical keratoconus based in binary logistic regression models.

104 rations (HOA's) are exaggerated in eyes with keratoconus but little is known about their impact on th

105 ), while 35 patients (19.1%) were labeled as keratoconus by objective analysis.

106 Data collected from patients with advanced keratoconus cases were studied during a minimum period o

107 toconic eyes from 191 patients with advanced keratoconus cases were studied.

108 Human corneal fibroblasts(HCFs) and human keratoconus cells(HKCs) were treated with a stable Vitam

109 A total of 126 patients from the keratoconus center of Homburg/Saar were evaluated with r

110 entacam (Keratoconus Index [KI], Topographic Keratoconus Classification [TKC]), Topographic Modeling

111 Amsler-Krumeich keratoconus classification was used to categorize the pa

112 d patients with keratoconus who attended the keratoconus clinic at the Antwerp University Hospital, B

113 ere observed in the corneas of patients with keratoconus compared with healthy corneas.

114 obese adolescents have higher odds of having keratoconus compared with normal weight adolescents.

115 tation is more effective in eyes with severe keratoconus compared with those with moderate keratoconu

116 Several anatomic features at the keratoconus cone were analyzed with OCT, including epith

117 ithelial thickening, stromal thinning at the keratoconus cone, anterior hyperreflectives at the Bowma

118 iopters (D) from baseline to 1 year, whereas keratoconus continued to progress in the control group.

119 stiffening of the cornea has been found and keratoconus corneas are statistically significantly diff

120 Keratoconus corneas have a significantly reduced Brillou

121 Genetic associations for keratoconus could be useful for understanding disease pa

122 agnosis between normal cases and subclinical keratoconus depends on the minimum corneal thickness, th

123 mpared to K(max) and thinnest pachymetry for keratoconus detection.

124 Repeatability in subclinical keratoconus did not differ significantly from controls (

125 ndications for PK between 1980 and 2014 were keratoconus (Europe, Australia, the Middle East, Africa,

126 oci that contribute to a cumulative risk for keratoconus, even in people without a family history of

127 ccount by the clinician in the evaluation of keratoconus eyes and in the planning of corneal keratopl

128 In forme fruste keratoconus eyes, the ART max is considered a highly sen

129 In the clinical keratoconus eyes, the mean K, back difference elevation

130 lasts (HCFs) from healthy patients and Human Keratoconus fibroblasts (HKCs) from KC patients.

131 gular corneal astigmatism and a patient with keratoconus following pars plana vitrectomy.

132 ), the formulas were ranked as follows: Kane keratoconus formula (0.81 D), SRK/T (1.00 D), Barrett Un

133 The Kane keratoconus formula had a statistically significant lowe

134 The Kane keratoconus formula was the most accurate formula in thi

135 all 3 machines can effectively differentiate keratoconus from normal corneas.

136 collagen crosslinking (CXL) for progressive keratoconus from the healthcare payer's perspective.

137 -RMS, PosICP-RMS and CM were correlated with keratoconus grade (p < 0.05).

138 ior ratio at 8 mm significantly increased as keratoconus grading increased (P < .001).

139 Thickness central 3 mm decreased as keratoconus grading increased (P = .002).

140 nt resulted in larger wRMS variations in the keratoconus group than in the normal group.

141 The keratoconus group was subdivided according to the Belin/

142 ected from 312 patients with normal corneas; Keratoconus group, including 1 eye randomly selected fro

143 corneal stromal cells derived from five non-Keratoconus healthy (HCF) and four Keratoconus (HKC) don

144 five non-Keratoconus healthy (HCF) and four Keratoconus (HKC) donors.

145 Fifteen participants had keratoconus in at least 1 eye, giving a prevalence of 1.

146 of focus (DOF)] of 12 subjects with manifest keratoconus in both eyes (KCE cohort), 9 subjects with v

147 eratoplasty (PKP) when indicated in managing keratoconus in Canada.

148 utic modality for the management of advanced keratoconus in children.

149 A total of 48 patients with clinical keratoconus in one eye and forme fruste keratoconus in t

150 Patients with clinical keratoconus in one eye and forme fruste keratoconus in t

151 The prevalence of keratoconus in pediatric first-degree relatives of diagn

152 The diagnosis of keratoconus in the early stages of the disease is necess

153 ical keratoconus in one eye and forme fruste keratoconus in the fellow eye and 72normal subjects were

154 ical keratoconus in one eye and forme fruste keratoconus in the fellow eye were compared to subjects

155 The prevalence of keratoconus in the general population was 164 cases per

156 : 11.6-15.2) and the estimated prevalence of keratoconus in the general population was 1:375 (265 cas

157 t or pathologic nerve morphology persists in keratoconus in the long term after corneal collagen cros

158 the age-specific incidence and prevalence of keratoconus in the modern era of diagnostics.

159 previous scleral buckling in one case and by keratoconus in the other case.

160 The prevalence of keratoconus in this Australian population-based study of

161 ide polymorphisms (SNPs) in 6 genes/loci for keratoconus in Whites.

162 en comparing normal corneas with early-stage keratoconus/ in variables of the vertical asymmetry to 9

163 5), index of surface variance (P < .05), and keratoconus index (P = .008) and decline in central corn

164 respect to Amsler criteria, using Pentacam (Keratoconus Index [KI], Topographic Keratoconus Classifi

165 rface variance, index of vertical asymmetry, keratoconus index, central keratoconus index, index of h

166 rtical asymmetry, keratoconus index, central keratoconus index, index of height asymmetry, and index

167 tional study of 19 patients with early-stage keratoconus indicated for a first CXL treatment with lon

168 We derived thresholds for the metric keratoconus indices KI and KMI, which allow classificati

169 Keratoconus indices measured by all 3 machines can effec

170 howed best correlation with geometry-derived keratoconus indices.

171 Keratoconus is a highly prevalent (1 in 2000), genetical

172 Posterior keratoconus is a rare cause of a corneal opacity in an i

173 Keratoconus is characterized by a neurotrophic deficit a

174 orneal collagen crosslinking for progressive keratoconus is cost effective at a willingness-to-pay th

175 Detailed knowledge of the natural history of keratoconus is fundamental in making informed decisions

176 Identification of risk genes for keratoconus is improving our understanding of the biolog

177 t populations - one from the Middle East, as keratoconus is particularly severe in this group, and th

178 47 patients (1 eye) with keratoconus (KC) and 20 healthy subjects (1 eye).

179 Keratoconus (KC) and chronic diabetes mellitus (DM) are

180 hy in successive measurements by Pentacam in keratoconus (KC) and normal eyes based on the Iterative

181 Keratoconus (KC) is a corneal thinning disease with an o

182 Keratoconus (KC) is a corneal thinning disorder that lea

183 Keratoconus (KC) is a multi-factorial corneal ectasia wi

184 Keratoconus (KC) is a progressive corneal disorder in wh

185 Keratoconus (KC) is classically considered a non-inflamm

186 Keratoconus (KC) is the most common corneal ectatic diso

187 Keratoconus (KC) is usually a bilateral corneal ectatic

188 ne the sociodemographic and risk factors for keratoconus (KC) patients with a nationwide Asian databa

189 tomography for the detection of sub-clinical keratoconus (KC) with a Zernike application method.

190 assify examinations of 3 categories: normal, keratoconus (KC), and history of refractive surgery (RS)

191 had undergone a first corneal transplant for keratoconus (KC), Fuchs endothelial dystrophy (FED), pse

192 ting metabolism and inflammatory pathways in Keratoconus (KC), which is a corneal thinning disease as

193 d corneal cross-linking (A-CXL) in pediatric keratoconus (KC).

194 by UHR-OCT in the diagnosis of sub-clinical keratoconus (KC).

195 nd aberrometric characteristics in pediatric keratoconus (KC).

196 ed as forme fruste (FFKc, n = 212) and overt keratoconus (Kc, n = 222).

197 Keratoconus(KC) is an ecstatic corneal disease leading t

198 emic diseases, sociodemographic factors, and keratoconus (KCN) among a large, diverse group of insure

199 Keratoconus (KCN) and Down syndrome affect the corneal d

200 alyzer (Keratoconus Match Probability [KMP], Keratoconus Match Index [KMI]).

201 Klyce/Maeda), and Ocular Response Analyzer (Keratoconus Match Probability [KMP], Keratoconus Match I

202 Laser automation of some steps in DALK for keratoconus may reduce the rate of intraoperative Descem

203 us Descemet s (basement) membrane rupture in keratoconus, mimicking this animal model and highlightin

204 Patients with progressive keratoconus (n = 205).

205 ed 612 eyes of 391 subjects with progressive keratoconus (n = 589), pellucid marginal degeneration (n

206 first systematic review and meta-analysis of keratoconus natural history data including 11 529 eyes.

207 IOL implantation in a vitrectomized eye with keratoconus nor of toric IOL implantation in patients wi

208 If CXL had a stabilizing effect on keratoconus of 15 years or longer, then the ICER would b

209 eyes, whereas Group 2 included 36 eyes with keratoconus of unclear progression.

210 t analysis of relevant corneal parameters in keratoconus of varying degrees.

211 Patients with progressive keratoconus or ectasia after refractive surgery (n = 510

212 Irregular corneal astigmatism in keratoconus or scleral-buckle-induced regular astigmatis

213 Keratoconus, suspected keratoconus, or its absence were determined in each pati

214 Total of 167 eyes, of which 107 were from keratoconus patients and 60 were healthy.

215 , consisting of 47 healthy volunteers and 38 keratoconus patients at differing stages of disease, ran

216 ediatric first-degree relatives of diagnosed keratoconus patients is high.

217 neous tPRK followed by CXL in this series of keratoconus patients offered significantly improved visi

218 nzaro, Italy); Study Population: Consecutive keratoconus patients undergoing BB-DALK from September 2

219 Twenty-nine keratoconus patients were randomized in three trial cent

220 A total of 37.5% of the keratoconus patients were unilateral as evaluated by tom

221 Keratoconus patients with an elongated posterior segment

222 ation followed by cross-linking in pediatric keratoconus patients.

223 Sixty-five eyes of 65 adult keratoconus patients.

224 asymmetry, skewed radial axis, logarithm of keratoconus percentage index, index of surface variance,

225 procedures (416 eyes) for the indication of keratoconus performed between January 2012 and January 2

226 for keratoplasty was more than halved in our keratoconus population.

227 Approximately 60% of patients with keratoconus post-keratoplasty experience doubling of the

228 am were statistically similar to that of the keratoconus prediction index (KPI) and keratoconus proba

229 f the keratoconus prediction index (KPI) and keratoconus probability (Kprob) of Galilei (P = .27) and

230 ng problems, 23% of cases showed a continued keratoconus progression after 1 year.

231 omechanical inhomogeneity in the cornea with keratoconus progression and biomechanical asymmetry betw

232 ion models to reflect the natural history of keratoconus progression and the impact of conventional m

233 and HuGENET databases for genetic studies of keratoconus published from 1950 to June 2016.

234 Keratoconus screening indices were evaluated using the P

235 Healthy patients and patients suffering from keratoconus seen at the Institut fur Refraktive und Opht

236 Recipient age, keratoconus severity, donor-related variables, recipient

237 ulas were analyzed in each eye stratified by keratoconus severity.

238 ned from multiple studies may lead to a core keratoconus signature of deregulated genes and a better

239 cations, were analyzed and compared based on keratoconus stage.

240 Groups were matched in terms of age and keratoconus stage.

241 corneas, but for precise differentiating of keratoconus stages (including normal corneas) the method

242 For separation of keratoconus stages 0/1/2/3/4 we derived the following op

243 44 subjects, graded from the first to third keratoconus stages by Amsler-Krumeich classification.

244 es KI and KMI, which allow classification of keratoconus stages.

245 discriminating between healthy (stage 0) and keratoconus (stages 2-4) eyes in comparison with the oth

246 aberrometry characteristics in patients with keratoconus, subclinical keratoconus and normal corneas.

247 In keratoconus subjects, contrast sensitivity displayed a s

248 In keratoconus subjects, the strongest correlation was for

249 l parameters determine the visual quality in keratoconus subjects.

250 elp to develop signatures and biomarkers for keratoconus subtypes.

251 Keratoconus, suspected keratoconus, or its absence were

252 Forty patients (44 eyes) with keratoconus that had serial evaluation for CCT, followin

253 ative outcomes were collected from eyes with keratoconus that had uncomplicated cataract surgery betw

254 Forty of the 51 eyes with severe keratoconus that would otherwise have undergone transpla

255 For subclinical keratoconus, the highest sensitivity (100%) was seen for

256 se of CXL in the management of patients with keratoconus, the progression of abnormal innervation aft

257 Population: Consecutive cases of keratoconus treated with big-bubble F-DALK from August 1

258 Consecutive cases of keratoconus treated with non-laser assisted DALK from Se

259 zed clinical trial enrolled 40 patients with keratoconus undergoing epi-off CXL from July 18, 2014, t

260 y, 138 eyes of 138 patients with progressive keratoconus underwent corneal collagen cross-linking (CX

261 The patients with keratoconus underwent standard epithelial-off UV-A/ribof

262 The annual incidence of keratoconus was 1:7500 in the relevant age category (13.

263 Mean (SD) age of the 19 patients with keratoconus was 27.5 (7.1) years (range, 19-44 years), a

264 Keratoconus was associated with regular cigarette smokin

265 agnostic and predictive model of early-stage keratoconus was calculated with the statistically signif

266 Diagnosis of bilateral keratoconus was confirmed by corneal topography.

267 Keratoconus was defined as a Belin/Ambrosio enhanced ect

268 and the annual incidence of newly diagnosed keratoconus was determined.

269 The prevalence of keratoconus was estimated based on the annual incidence,

270 in the corneas of patients with stage 1 or 2 keratoconus was reduced 51% (mean difference, 10.7 mm/mm

271 Highest sensitivity (100%) to diagnose keratoconus was seen for 6 parameters on Pentacam and 1

272 Keratoconus was the leading indication in Europe (24.2%)

273 h the annual incidence and the prevalence of keratoconus were 5-fold to 10-fold higher than previousl

274 The odds for having keratoconus were compared with the normal weight group.

275 A total of 56 eyes in 56 patients with keratoconus were included.

276 eal cross-linking for halting progression of keratoconus were investigated in a prospective, randomiz

277 Mild cases of keratoconus were more prone to be explanted because of a

278 cal and topographic abnormalities similar to keratoconus were observed in 14 eyes (58.3%) of 8 WFS pa

279 Older age and advanced stages of keratoconus were predictors of type 2 bubble formation d

280 our eyes of 25 participants with progressive keratoconus were randomized into T-ionto CL (22 eyes) or

281 infectious corneal scarring and thinning and keratoconus were the most common diagnoses.

282 Thirty-one eyes with keratoconus were treated with an accelerated protocol (1

283 patients with documented progressive primary keratoconus were treated with customized CXL (n = 20) or

284 virtual patients with progressive bilateral keratoconus, were modeled; one cohort underwent CXL and

285 Study population comprised patients with keratoconus who attended the keratoconus clinic at the A

286 imulated cohorts of 100 000 individuals with keratoconus who entered each treatment arm at 25 years o

287 Data from patients with keratoconus who had preoperative IOLMaster biometry were

288 , pseudophakic bullous keratopathy (PBK), or keratoconus who had undergone a penetrating keratoplasty

289 s study included 36 eyes in 36 patients with keratoconus who underwent DALK using the big-bubble tech

290 ed 194 consecutive eyes of 181 patients with keratoconus who underwent DALK using the big-bubble tech

291 rospective study that included patients with keratoconus who underwent FSAK for astigmatism following

292 (2) = 21.51%, P < .001) were associated with keratoconus with a combined area under the curve of 0.92

293 A total of 245 eyes underwent PK for keratoconus with mean follow-up of 5.6 +/- 3.6 years.

294 al of 158 eyes/150 consecutive patients with keratoconus with postoperative follow-up time equal to o

295 ed significant in multivariate analysis were keratoconus with scarring (odds ratio [OR] = 3.56, P = .

296 rring (odds ratio [OR] = 3.56, P = .02), non-keratoconus with scarring (OR = 5.09, P = .002), intraop

297 on-keratoconus without scarring; and (4) non-keratoconus with scarring.

298 zed as (1) keratoconus without scarring; (2) keratoconus with scarring; (3) non-keratoconus without s

299 ications for surgery were categorized as (1) keratoconus without scarring; (2) keratoconus with scarr

300 ring; (2) keratoconus with scarring; (3) non-keratoconus without scarring; and (4) non-keratoconus wi